Kesimpta vs Tecfidera
Side-by-side cost comparison based on Medicare Part D data
Kesimpta
Ofatumumab
Manufactured by Novartis
Tecfidera
Dimethyl Fumarate
Manufactured by Biogen
Tecfidera costs 51% less per claim than Kesimpta ($4,103.00 vs $8,425.00). A generic version of Tecfidera is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Kesimpta | Tecfidera |
|---|---|---|
| Avg Cost Per Claim | $8,425.00 | $4,103.00 |
| Total Medicare Spending | $1.6B | $1.8B |
| Total Beneficiaries | 22,000 | 38,000 |
| Total Claims | 186,000 | 428,000 |
| Annual Cost/Patient | $71,227.00 | $46,211.00 |
| Year-over-Year Change | +68.4% | -28.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Apr 12, 2024 |
| Manufacturer | Novartis | Biogen |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Ofatumumab | Dimethyl Fumarate |
Kesimpta vs Tecfidera: What the Data Shows
Kesimpta (Ofatumumab) and Tecfidera (Dimethyl Fumarate) are both used to treat multiple sclerosis. Based on Medicare Part D data, Tecfidera costs $4,103.00 per claim, which is 51% less than Kesimpta at $8,425.00 per claim.
Medicare spent $1.6B on Kesimpta and $1.8B on Tecfidera. In terms of patient reach, Tecfidera serves more beneficiaries (38,000 vs 22,000).
Year-over-year spending changed +68.4% for Kesimpta and -28.4% for Tecfidera. Kesimpta saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Tecfidera is cheaper at $4,103.00 per claim, compared to $8,425.00 for Kesimpta. That makes Tecfidera about 51% less expensive per claim based on Medicare Part D data.
Yes, both Kesimpta and Tecfidera are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ofatumumab and generic Dimethyl Fumarate can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $1.6B on Kesimpta covering 22,000 beneficiaries, and $1.8B on Tecfidera covering 38,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Kesimpta and Tecfidera. What follows is the interpretation — which specific axes carry the most weight for Kesimpta versus Tecfidera, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.